Verona Pharma Plc ADR [VRNA] stock is trading at $42.68, up 3.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRNA shares have gain 6.17% over the last week, with a monthly amount glided 20.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on October 03, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $50. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $31 on August 26, 2022. H.C. Wainwright initiated its recommendation with a Buy and recommended $25 as its price target on September 13, 2021. Jefferies started tracking with a Buy rating for this stock on August 25, 2020, and assigned it a price target of $17. In a note dated August 10, 2020, Canaccord Genuity initiated an Buy rating and provided a target price of $17 on this stock.
Verona Pharma Plc ADR [VRNA] stock has fluctuated between $11.39 and $41.64 over the past year. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $42.68 at the most recent close of the market. An investor can expect a potential drop of -7.45% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -23.71%, Pretax Profit Margin comes in at -23.53%, and Net Profit Margin reading is -23.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.8 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.38 points at the first support level, and at 40.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.86, and for the 2nd resistance point, it is at 45.03.
Ratios To Look Out For
For context, Verona Pharma Plc ADR’s Current Ratio is 13.03. On the other hand, the Quick Ratio is 13.03, and the Cash Ratio is 12.02. Considering the valuation of this stock, the price to sales ratio is 614.88, the price to book ratio is 26.76.
Transactions by insiders
Recent insider trading involved ZACCARDELLI DAVID, President and CEO, that happened on Dec 05 ’24 when 0.64 million shares were sold. President and CEO, ZACCARDELLI DAVID completed a deal on Dec 06 ’24 to sell 0.16 million shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 67608.0 shares on Dec 04 ’24.
